Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
240 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Traumatic Brain Injury - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Traumatic Brain Injury - Pipeline Review, H2 2014', provides an overview of the Traumatic Brain Injury's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Traumatic Brain Injury and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Traumatic Brain Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Traumatic Brain Injury pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Traumatic Brain Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Traumatic Brain Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Traumatic Brain Injury Overview 9 Therapeutics Development 10 Pipeline Products for Traumatic Brain Injury - Overview 10 Pipeline Products for Traumatic Brain Injury - Comparative Analysis 11 Traumatic Brain Injury - Therapeutics under Development by Companies 12 Traumatic Brain Injury - Therapeutics under Investigation by Universities/Institutes 15 Traumatic Brain Injury - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Traumatic Brain Injury - Products under Development by Companies 21 Traumatic Brain Injury - Products under Investigation by Universities/Institutes 25 Traumatic Brain Injury - Companies Involved in Therapeutics Development 26 Acorda Therapeutics, Inc. 26 Adamas Pharmaceuticals, Inc. 27 ALSP, Inc. 28 Amarantus Bioscience Holdings, Inc. 29 Athersys, Inc. 30 BHR Pharma, LLC 31 Cognosci, Inc. 32 Concert Pharmaceuticals, Inc. 33 Encore Therapeutics Inc. 34 Euroscreen S.A. 35 Grupo Ferrer Internacional, S.A. 36 International Stem Cell Corporation 37 Io Therapeutics, Inc. 38 Ischemix 39 Lixte Biotechnology Holdings, Inc. 40 Lpath, Inc. 41 MandalMed, Inc. 42 Mapreg S.A.S. 43 Mnemosyne Pharmaceuticals, Inc. 44 NeoStem, Inc. 45 Neuralstem, Inc. 46 Neuren Pharmaceuticals Limited 47 NeuroHealing Pharmaceuticals Inc. 48 NeuroNascent, Inc. 49 NeuroVive Pharmaceutical AB 50 Omeros Corporation 51 PharmatrophiX, Inc. 52 Phylogica Limited 53 Prevacus, Inc. 54 PsychoGenics, Inc. 55 QR Pharma, Inc. 56 RegeneRx Biopharmaceuticals, Inc. 57 Remedy Pharmaceuticals, Inc. 58 Sage Therapeutics 59 SanBio, Inc. 60 STATegics, Inc. 61 SynZyme Technologies, LLC 62 Tetra Discovery Partners LLC 63 vasopharm GmbH 64 VG Life Sciences, Inc. 65 Voltarra Pharmaceuticals, Inc. 66 Traumatic Brain Injury - Therapeutics Assessment 67 Assessment by Monotherapy Products 67 Assessment by Combination Products 68 Assessment by Target 69 Assessment by Mechanism of Action 71 Assessment by Route of Administration 74 Assessment by Molecule Type 76 Drug Profiles 78 2-DG - Drug Profile 78 AC-105 - Drug Profile 80 ADS-8800 Series - Drug Profile 81 ALP-496 - Drug Profile 82 amantadine hydrochloride ER - Drug Profile 83 AMR-001 - Drug Profile 85 AMRS-001 - Drug Profile 87 apomorphine hydrochloride - Drug Profile 89 AVL-8168 - Drug Profile 91 BHR-100 - Drug Profile 92 BHR-310 - Drug Profile 93 C-10068 - Drug Profile 94 Cell Therapy to Activate Neurotrophic Factor for Spinal Cord and Traumatic Brain Injury - Drug Profile 95 CMX-2043 - Drug Profile 96 CNB-001 - Drug Profile 98 COG-1410 - Drug Profile 100 cyclosporine - Drug Profile 102 dexamethasone acetate + melatonin - Drug Profile 105 EPO-Variant - Drug Profile 106 ESN-502 - Drug Profile 107 felbamate - Drug Profile 108 FIB-117 - Drug Profile 109 glyburide - Drug Profile 110 HBN-1 - Drug Profile 112 HBN-2 - Drug Profile 113 ICCN-100 - Drug Profile 114 IRX-4204 - Drug Profile 115 LB-201 - Drug Profile 117 LB-205 - Drug Profile 118 LM11A-31 - Drug Profile 119 Lpathomab - Drug Profile 120 MAP-4343 - Drug Profile 121 MultiStem - Drug Profile 122 ND-478 - Drug Profile 125 NNI-370 - Drug Profile 126 NNZ-2566 - Drug Profile 127 NNZ-2591 - Drug Profile 129 NSI-189 - Drug Profile 131 NSI-566 - Drug Profile 132 NVP-019 - Drug Profile 134 NVX-428 - Drug Profile 135 Peptides to Inhibit Major Histocompatibility Complex Class I and II for Central Nervous System and Musculoskeletal Disorders - Drug Profile 136 PGI-02776 - Drug Profile 137 Posiphen - Drug Profile 139 progesterone - Drug Profile 141 PRV-001 - Drug Profile 142 PYC-35 - Drug Profile 143 PYC-36 - Drug Profile 144 PYC-38 - Drug Profile 145 PYC-98 - Drug Profile 146 R-503 - Drug Profile 147 RGN-352 - Drug Profile 149 SAGE-547 - Drug Profile 151 SB-623 - Drug Profile 153 Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 154 Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 155 Small Molecule to Antagonize NMDA2A for Central Nervous System Disorder - Drug Profile 156 Small Molecule to Inhibit Amyloid Beta Peptide for Traumatic Brain Injury and Alzheimer's Disease - Drug Profile 157 Small Molecule to Inhibit PDE4 for Traumatic Brain Injury - Drug Profile 158 Small Molecules for Stroke and Traumatic Brain Injury - Drug Profile 159 Small Molecules to Activate P2Y Receptor for Stroke and Traumatic Brain Injury - Drug Profile 160 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 161 Small Molecules to Inhibit BACE-1 for Alzheimer's Disease and Traumatic Brain Injury - Drug Profile 162 Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile 163 Stem Cell Therapy for Central Nervous System Disorders - Drug Profile 164 Stem Cell Therapy for Parkinson's Disease, Traumatic Brain Injury and Stroke - Drug Profile 165 STSE-15 - Drug Profile 166 TBI-121 - Drug Profile 167 TBI-122 - Drug Profile 168 TBI-123 - Drug Profile 169 VAS-203 - Drug Profile 170 VG-1177 - Drug Profile 172 VitalHeme - Drug Profile 174 VOLT-02 - Drug Profile 176 Traumatic Brain Injury - Recent Pipeline Updates 177 Traumatic Brain Injury - Dormant Projects 222 Traumatic Brain Injury - Discontinued Products 225 Traumatic Brain Injury - Product Development Milestones 226 Featured News & Press Releases 226 Appendix 234 Methodology 234 Coverage 234 Secondary Research 234 Primary Research 234 Expert Panel Validation 234 Contact Us 235 Disclaimer 235
List of Tables Number of Products under Development for Traumatic Brain Injury, H2 2014 15 Number of Products under Development for Traumatic Brain Injury - Comparative Analysis, H2 2014 16 Number of Products under Development by Companies, H2 2014 17 Number of Products under Development by Companies, H2 2014 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2014 21 Comparative Analysis by Late Stage Development, H2 2014 22 Comparative Analysis by Clinical Stage Development, H2 2014 23 Comparative Analysis by Early Stage Development, H2 2014 24 Comparative Analysis by Unknown Stage Development, H2 2014 25 Products under Development by Companies, H2 2014 26 Products under Development by Companies, H2 2014 (Contd..1) 27 Products under Development by Companies, H2 2014 (Contd..2) 28 Products under Development by Companies, H2 2014 (Contd..3) 29 Products under Investigation by Universities/Institutes, H2 2014 30 Traumatic Brain Injury - Pipeline by Acorda Therapeutics, Inc., H2 2014 31 Traumatic Brain Injury - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 32 Traumatic Brain Injury - Pipeline by ALSP, Inc., H2 2014 33 Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 34 Traumatic Brain Injury - Pipeline by Athersys, Inc., H2 2014 35 Traumatic Brain Injury - Pipeline by BHR Pharma, LLC, H2 2014 36 Traumatic Brain Injury - Pipeline by Cognosci, Inc., H2 2014 37 Traumatic Brain Injury - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 38 Traumatic Brain Injury - Pipeline by Encore Therapeutics Inc., H2 2014 39 Traumatic Brain Injury - Pipeline by Euroscreen S.A., H2 2014 40 Traumatic Brain Injury - Pipeline by Grupo Ferrer Internacional, S.A., H2 2014 41 Traumatic Brain Injury - Pipeline by International Stem Cell Corporation, H2 2014 42 Traumatic Brain Injury - Pipeline by Io Therapeutics, Inc., H2 2014 43 Traumatic Brain Injury - Pipeline by Ischemix, H2 2014 44 Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 45 Traumatic Brain Injury - Pipeline by Lpath, Inc., H2 2014 46 Traumatic Brain Injury - Pipeline by MandalMed, Inc., H2 2014 47 Traumatic Brain Injury - Pipeline by Mapreg S.A.S., H2 2014 48 Traumatic Brain Injury - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2014 49 Traumatic Brain Injury - Pipeline by NeoStem, Inc., H2 2014 50 Traumatic Brain Injury - Pipeline by Neuralstem, Inc., H2 2014 51 Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Limited, H2 2014 52 Traumatic Brain Injury - Pipeline by NeuroHealing Pharmaceuticals Inc., H2 2014 53 Traumatic Brain Injury - Pipeline by NeuroNascent, Inc., H2 2014 54 Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H2 2014 55 Traumatic Brain Injury - Pipeline by Omeros Corporation, H2 2014 56 Traumatic Brain Injury - Pipeline by PharmatrophiX, Inc., H2 2014 57 Traumatic Brain Injury - Pipeline by Phylogica Limited, H2 2014 58 Traumatic Brain Injury - Pipeline by Prevacus, Inc., H2 2014 59 Traumatic Brain Injury - Pipeline by PsychoGenics, Inc., H2 2014 60 Traumatic Brain Injury - Pipeline by QR Pharma, Inc., H2 2014 61 Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2014 62 Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals, Inc., H2 2014 63 Traumatic Brain Injury - Pipeline by Sage Therapeutics, H2 2014 64 Traumatic Brain Injury - Pipeline by SanBio, Inc., H2 2014 65 Traumatic Brain Injury - Pipeline by STATegics, Inc., H2 2014 66 Traumatic Brain Injury - Pipeline by SynZyme Technologies, LLC, H2 2014 67 Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H2 2014 68 Traumatic Brain Injury - Pipeline by vasopharm GmbH, H2 2014 69 Traumatic Brain Injury - Pipeline by VG Life Sciences, Inc., H2 2014 70 Traumatic Brain Injury - Pipeline by Voltarra Pharmaceuticals, Inc., H2 2014 71 Assessment by Monotherapy Products, H2 2014 72 Assessment by Combination Products, H2 2014 73 Number of Products by Stage and Target, H2 2014 75 Number of Products by Stage and Mechanism of Action, H2 2014 77 Number of Products by Stage and Route of Administration, H2 2014 80 Number of Products by Stage and Molecule Type, H2 2014 82 Traumatic Brain Injury Therapeutics - Recent Pipeline Updates, H2 2014 182 Traumatic Brain Injury - Dormant Projects, H2 2014 227 Traumatic Brain Injury - Dormant Projects (Contd..1), H2 2014 228 Traumatic Brain Injury - Dormant Projects (Contd..2), H2 2014 229 Traumatic Brain Injury - Discontinued Products, H2 2014 230
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
